About: Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article

Attributes	Values
rdf:type	Item
description	article (en) հոդված (hy) wetenschappelijk artikel (nl) наукова стаття, опублікована в серпні 2012 (uk) im August 2012 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q58912330-8406C51E-C0B3-48ED-AE97-D559DF78352A
publication date	2012-08-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q58912330-DB42B15E-C2BF-4945-BC65-146989B5B859
language of work or name	English
author name string	wds:Q58912330-0760E34B-AF69-4574-9041-C4A92F0C2950 wds:Q58912330-193AAE5F-C564-4AA6-855F-420AF8E119F7 wds:Q58912330-1BCCEE57-1621-4288-840A-20054BE035BD wds:Q58912330-2EE2C559-2F5B-41FB-9518-CE6E3FF95F41 wds:Q58912330-412E4728-F01D-4895-9F88-F3DAFD5DCA3A wds:Q58912330-5017706B-27AE-42F3-9802-C1E5FA4E274B wds:Q58912330-504462C4-0178-4EA9-B939-4B0A2C5BDD7A wds:Q58912330-50B54450-BDFD-4BFD-8C3B-177CBA1F4781 wds:Q58912330-665C0A2B-74A2-449A-B9EA-7359189E5EEF wds:Q58912330-6AA65995-DFBC-420D-9303-F6420BC18E14 wds:Q58912330-B2D014FE-4C0E-45B1-AB22-F63726032E23 wds:Q58912330-B86E3616-405B-4139-876D-2F1A8FA43D7B wds:Q58912330-EFDF4507-A47A-4159-ADAB-DEFE98F69A66 wds:Q58912330-F7C92F39-54DD-4291-B402-455769913322
author name string	Ronald F van Vollenhoven Sriram Krishnaswami Eun Bong Lee Roy Fleischmann Samuel H Zwillich Tamas Koncz Bethanie Wilkinson David Gruben Gene V Wallenstein John D Bradley Sylke Wagner Juan A García Meijide ORAL Standard Investigators Sarka Forejtova
rdfs:label	Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis (en) Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis (nl)
skos:prefLabel	Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis (en) Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis (nl)
name	Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis (en) Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis (nl)
author	wds:Q58912330-1432BF7A-0C7F-4FDB-856D-E55B54F610FC
author	Stanley B Cohen
title	wds:Q58912330-18481A20-3D30-4B33-AB5A-A53C44015A8F
title	Tofacitinib or adalimumab versus placebo in rheumatoid arthritis (en)
page(s)	wds:Q58912330-48495A25-A7FC-4E2E-B14F-B19D127D90F8
page(s)	508-519
instance of	wds:Q58912330-6F24899A-9C1E-48D5-A3D4-51F751E9E587
instance of	scholarly article
main subject	wds:Q58912330-0BC0F68E-4066-414A-87F3-A23EB625DB6C wds:Q58912330-1803A35C-A9F5-486B-BA08-B373DCBBDC3A wds:Q58912330-81A0B96D-7487-4B76-8114-ADBD5B16DE5E wds:Q58912330-F52B800A-6C58-427E-B347-8297737AAD9E
main subject	wd:Q3530324 rheumatoid arthritis placebo adalimumab
PubMed ID	wds:Q58912330-638F98AA-1815-46A4-8261-241B8F7FEEB1
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/22873531
PubMed ID	22873531
published in	wds:Q58912330-5E0C4255-B51A-438F-AE4E-8B064D66FDFE
published in	The New England Journal of Medicine
issue	wds:Q58912330-ADC68F41-D548-46C1-A7D3-8C556E030F67
volume	wds:Q58912330-85B81725-3A3C-4DA7-B504-5251BD7D6046
issue	6
volume	367
number of pages	wds:Q58912330-83A97E63-B9DA-48C9-BCAD-917ADFA15089
number of pages	12 (xsd:decimal)
DOI	wds:Q58912330-84323938-9491-4B9B-9903-B87C4DD74314
DOI	http://dx.doi.org/10.1056/NEJMOA1112072
DOI	10.1056/NEJMOA1112072
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q58912330
is cites work of	Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis Tumor necrosis factor α induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts Mechanisms and management of refractory coeliac disease Janus kinases: an ideal target for the treatment of autoimmune diseases. Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis. What's fueling the biotech engine-2011 to 2012. Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Disease-specific mutations in mature lymphoid neoplasms: recent advances Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis Validating therapeutic targets through human genetics Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment New anti-inflammatory targets for chronic obstructive pulmonary disease. Advances in the treatment of rheumatoid arthritis. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software